Amring Pharms Company Profile
✉ Email this page to a colleague
What is the competitive landscape for AMRING PHARMS, and what generic alternatives to AMRING PHARMS drugs are available?
AMRING PHARMS has fourteen approved drugs.
There are eight US patents protecting AMRING PHARMS drugs.
There are eight patent family members on AMRING PHARMS drugs in two countries and thirty supplementary protection certificates in ten countries.
Summary for Amring Pharms
| International Patents: | 8 |
| US Patents: | 8 |
| Tradenames: | 13 |
| Ingredients: | 13 |
| NDAs: | 14 |
Drugs and US Patents for Amring Pharms
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Amring Pharms | LYSTEDA | tranexamic acid | TABLET;ORAL | 022430-001 | Nov 13, 2009 | AB | RX | Yes | Yes | 8,791,160 | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||
| Amring Pharms | LYSTEDA | tranexamic acid | TABLET;ORAL | 022430-001 | Nov 13, 2009 | AB | RX | Yes | Yes | 9,060,939 | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||
| Amring Pharms | ISOPROTERENOL HYDROCHLORIDE | isoproterenol hydrochloride | INJECTABLE;INJECTION | 211237-001 | May 19, 2021 | AP | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Paragraph IV (Patent) Challenges for AMRING PHARMS drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Tablets | 650 mg | ➤ Subscribe | 2011-05-24 |
International Patents for Amring Pharms Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Japan | 2008508276 | ⤷ Try a Trial |
| Japan | 5205053 | ⤷ Try a Trial |
| Japan | 2008508275 | ⤷ Try a Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Amring Pharms Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1586316 | C 2011 004 | Romania | ⤷ Try a Trial | PRODUCT NAME: BROMFENAC, SARURILE SI HIDRATII SAI ACCEPTABILI FARMACEUTICACID 2-[2-AMINO-3-(4-BROMOBENZOIL)FENILACETIC; NATIONAL AUTHORISATION NUMBER: RO EU/1/11/692/001; DATE OF NATIONAL AUTHORISATION: 20110518; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EMEA EU/1/11/692/001; DATE OF FIRST AUTHORISATION IN EEA: 20110518 |
| 3461484 | 301101 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: LATANOPROST OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN EN NETARSUDILMESYLAAT; REGISTRATION NO/DATE: EU/1/20/1502 20210108 |
| 0364417 | SPC/GB97/014 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: LATANOPROST (I.E. 13,14-DIHYDRO-17-PHENYL-18,19,20-TRINOR-PGF-ALPHA-ISOPROPYLESTER); NAT. REGISTRATION NO/DATE: 00032/0220 19961216; FIRST REGISTRATION: SE 12716 19960718; SPC EXTENSION AUTHORISATION: PL00057/1057-008 20101216 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
